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Although initially described as a cytosolic scaffolding
protein, YAP (Yes-associated protein of 65 kDa) is
known to associate with multiple transcription factors
in the nucleus. Using affinity chromatography and mass
spectrometry, we show that YAP interacts with hetero-
geneous nuclear ribonuclear protein U (hnRNP U), an
RNA- and DNA-binding protein enriched in the nuclear
matrix that also plays a role in the regulation of gene
expression. hnRNP U interacts specifically with the pro-
line-rich amino terminus of YAP, a region of YAP that is
not found in the related protein TAZ. Although hnRNP U
and YAP localize to both the nucleus and the cytoplasm,
YAP does not translocate to the nucleus in an hnRNP
U-dependent manner. Furthermore, hnRNP U and YAP
only interact in the nucleus, suggesting that the associ-
ation between the two proteins is regulated. Co-expres-
sion of hnRNP U attenuates the ability of YAP to in-
crease the activity of a p73-driven Bax-luciferase
reporter plasmid. In contrast, hnRNP U has no effect
when co-expressed with a truncated YAP protein lack-
ing the hnRNP U-binding site. Because YAP is distin-
guished from the homologue TAZ by its proline-rich
amino terminus, the YAP-hnRNP U interaction may
uniquely regulate the nuclear function(s) of YAP. The
YAP-hnRNP U interaction provides another mechanism
of YAP transcriptional regulation.
Gene expression is regulated through a variety of mecha-
nisms including the modulation of transcription factor localiza-
tion, post-translational processing, and turnover (1–3). In ad-
dition, transcription factors may associate with a large number
of protein co-factors that either enhance or repress transcrip-
tional activity in a cell type-specific context (4, 5). These asso-
ciations function in part to localize transcription factors to
specific protein complexes and can recruit proteins of the basal
transcription machinery. In addition, specific protein interac-
tions can modulate the localization of transcription factors in
the nucleus or cytoplasm and play an important role in the
integration of signal transduction cues.
One protein recently shown to function as a modulator of
multiple transcription factors in a variety of cell types is YAP
(Yes-associated protein of 65 kDa). YAP is a modular adaptor
protein with multiple protein interaction domains that was
originally isolated based on its ability to bind the SH3 domain
of the Src family kinase c-Yes (6). In addition to its SH3-
binding motif, YAP contains a proline-rich amino terminus, a
14-3-3-binding site, one (YAP1) or two (YAP2) WW domains
(hereafter, YAP will refer to YAP1), a coiled-coil, and a PDZ
interaction motif at the extreme COOH terminus (7–9). Al-
though initially thought to play a role in the anchoring and or
targeting of c-Yes to specific subcellular compartments, many
studies suggest that YAP plays a role in the regulation of gene
expression through its ability to associate with a broad array of
transcription factors (7, 10–14). These interactions typically
involve either of the two YAP WW domains that associate
directly with PPxY motifs within the transcription factors, but
other mechanisms of interaction also occur (7, 11–14). In a
two-hybrid screen, YAP was found to associate with PEBP2
(polyomavirus enhancer-binding protein 2), a transcription fac-
tor important for hematopoiesis and osteogenesis (14, 15). In
vivo, YAP enhanced the transcriptional activity of PEBP2,
and this enhancement required an association of the YAP WW
domain with the PPxY motif of the transcription factor. Like-
wise, overexpression of YAP increased the transcriptional ac-
tivity of the TEAD/TEF family of transcription factors and
endogenous YAP co-purified with overexpressed TEAD-2 in a
cell culture model system (12). The long forms of p73, homo-
logues of the p53 tumor-suppressor gene, also interact with
YAP via its WW domain (10, 13). Like p53, p73 proteins can
induce several anti-proliferative effects, such as cell cycle ar-
rest, apoptosis, and cellular differentiation (16–19). However,
the mechanisms underlying p73 protein stability are distinct
from p53; the two proteins differentially regulate gene expres-
sion (20, 21) and have distinct binding partners (22, 23).
Co-expression of YAP enhanced transcription of Bax and
mdm2 by p73 and p73 but had no effect on p53-mediated
gene transcription (13).
Although YAP can modulate the activity of multiple tran-
scription factors, several studies suggest that it localizes pre-
dominantly in the cytoplasm. For example, in airway epithelial
cells, YAP associates via its PDZ interaction motif with EBP50
(ezrin/radixin/moesin-binding phosphoprotein of 50 kDa), a
scaffolding protein localized predominantly to the apical mem-
brane (8). YAP also associates with cytoplasmic 14-3-3 proteins
(10) involved in multiple cellular processes such as signal
transduction, cell cycle control, and apoptosis (for reviews see
Refs. 24 and 25). 14-3-3 binds phosphorylated serine or threo-
nine residues on target proteins, often sequestering the protein
or maintaining it in an inactive state (26, 27). In the case of
YAP, binding by 14-3-3 sequesters YAP in the cytoplasm and
prevents it from entering the nucleus (10). The 14-3-3-binding
site on YAP is also a phosphorylation site for Akt; phosphoryl-
ation by Akt attenuates p73-mediated transcription by YAP in
U2OS cells (10).
YAP interacts with multiple proteins in the nucleus and in
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the cytoplasm and is an adaptor protein with many potential
functions in vivo. Many of these functions are likely shared by
a paralogue of YAP called TAZ (transcriptional co-activator
with a PDZ-binding motif). The two human proteins are 45%
identical and share many functional sequence domains and
motifs (28). TAZ also binds 14-3-3 and was originally identified
in a screen for novel 14-3-3-binding proteins (28). In addition,
TAZ and YAP both bind E3KARP (NHE3 kinase A regulatory
protein), a closely related member of the EBP50 family (29).
Furthermore, the predicted ligand-binding sequence of the TAZ
WW domain is similar to that of the YAP WW domain, and TAZ
also functions to enhance the transcriptional activity of
PEBP2 in vivo (28). Thus the two proteins likely share many
overlapping functions. Although the two proteins differ in their
ability to bind c-Yes (28), another difference between YAP and
TAZ is that YAP contains a proline-rich amino terminus that is
not found in TAZ. To identify protein interactions in this re-
gion, we used fusion proteins made to the first 57 amino acid
sequence of human YAP in biochemical screens to identify
novel YAP-associated proteins. We find that the proline-rich
amino terminus of YAP associates with heterogeneous nuclear
ribonucleoprotein U (hnRNP U),1 a protein that is enriched in
the nuclear matrix and has been shown to regulate gene tran-
scription (30–33). hnRNP U binds conserved AT-rich regions
within the genome called scaffold attachment regions, which
allow chromatin to attach to the nuclear matrix and form
5–200-kb loops (34). Indeed, hnRNP U was identified inde-
pendently as a protein that was capable of binding these scaf-
fold attachment region elements and named scaffold attach-
ment factor A (35). The interaction of YAP and hnRNP U
expands the association of YAP with nuclear proteins beyond
those that function as transcription factors and provides an
alternate mechanism whereby YAP may modulate gene expres-
sion in cells.
MATERIALS AND METHODS
Cell Culture and Immunofluorescence—The cells were maintained as
described previously (8, 36). Immunofluorescence and confocal micros-
copy were performed as described previously (8, 36) using the antibod-
ies and dilutions described below.
Antibodies and Reagents—YAP antisera were generated in rabbits
using GST-tagged human YAP(274–454) as immunogen. Recombinant
fusion protein was purified from the soluble fraction of bacterial lysates
on glutathione agarose beads, and the purified protein was injected into
two New Zealand White rabbits (Covance, Princeton, NJ). Serum
(NC252) was further purified on DEAE ion exchange and GST-
YAP(274–454) affinity columns and used for Western blotting (1:1000),
immunofluorescence (1:500), and immunoprecipitation (2 g). The
anti-hnRNP U monoclonal antibody 3G6 was a gift from Dr. Gideon
Dreyfuss (University of Pennsylvania) and used at 1:20000 dilution. All
other antisera were obtained from commercial sources.
The pGL3-Bax luciferase construct was a gift from Dr. Giovanni
Blandino from the Regina Elena Cancer Institute (Rome, Italy). A
-actin-LacZ plasmid expressing -galactosidase under control of hu-
man -actin promoter was a gift from Dr. Keith Yamamoto (University
of San Francisco), and the triple-tandem GFP (3XGFP) vector was a gift
from Dr. Yuri Lazebnik (Cold Spring Harbor Laboratory).
cDNAs encoding full-length human YAP and full-length human
hnRNP U were generated by PCR and cloned into the SalI and NotI
sites of pCMV.HA (Clontech, Palo Alto, CA). Plasmids containing the
amino terminus (amino acids 1–57) and WW1 domain (amino acids
162–217) of human YAP fused to GST were generated by PCR and
cloned into the SalI and NotI sites of pGEX.5X2 (Amersham Bio-
sciences). cDNAs encoding fragments of YAP for expression in mam-
malian cells were generated by PCR and cloned into the BamHI site of
the 3XGFP plasmid. The sequences of all plasmids were verified at the
University of North Carolina sequencing facility.
Affinity Purification of YAP-interacting Proteins and Immunoprecipi-
tation Analysis—The expression of GST, GST-YAP(1–57), and GST-
YAP(162–217) fusion proteins was induced for 3 h with 1 mM isopropyl-
-D-thiogalactopyranoside at 25 °C in terrific broth. The proteins were
harvested by sonication in phosphate-buffered saline containing 0.5%
Triton X-100 and 0.1 mM phenylmethylsulfonyl fluoride, 5 g/ml apro-
tinin, 5 g of leupeptin, 2 g/ml pepstatin A, and 2 g/ml benzamidine.
The soluble fusion protein was purified on glutathione-Sepharose
beads, and initial pull-down assays were performed using 20 g of
purified fusion protein. The cell lysates were prepared from a single
100-mm dish of 16HBE14o cells labeled with [32P]orthophosphate for
3 h in serum-free and phosphate-free Dulbecco’s modified Eagle’s me-
dium (Sigma). The cells were lysed in RIPA buffer (50 mM Tris, pH 7.0,
150 mM NaCl, 1 mM EDTA, 1.0% Nonidet P-40, 0.5% sodium deoxy-
cholate, 0.1% SDS), and the lysates were diluted 1:5 in binding buffer
(50 mM Tris, pH 7.0, 0.1% Triton X-100, 150 mM NaCl, 1 mM EDTA).
The assays were performed as described previously (8, 37), and the
proteins bound to GST, GST-YAP(1–57), and GST-YAP(162–217) were
compared by SDS-PAGE and visualized by silver staining (Amersham
Biosciences) or PhosphorImager analysis. For mass spectrometric anal-
ysis, 100 g of GST and GST-YAP(1–57) were used in pull-down assays
as described above except that the cell lysate was prepared from 30 
100-mm dishes of 16HBE14o cells. After extensive washing, the
bound fraction was analyzed by SDS-PAGE, and the proteins were
visualized with 0.01% colloidal Coomassie in 10% acetic acid. The
visible bands were excised, and the samples were analyzed by MALDI-
TOF-MS (Bruker Instruments Co., Bremen, Germany) and Nano-ESI-
MS/MS on an API QSTAR-Pulsar (QSTAR, Applied Biosystems Div.,
Perkin-Elmer Corp., Foster City, CA) as described (38).
For immunoprecipitations, HeLa cells were transfected for 18 h with
plasmid vectors encoding HA-YAP. The cells were washed in phos-
phate-buffered saline, scraped into 1 ml of phosphate-buffered saline
and centrifuged 1000  g for 4 min. Cytosol was extracted with cyto-
plasmic extraction buffer (10 mM Hepes, pH 7.6, 60 mM KCl, 1 mM
EDTA, 0.2% Nonidet P-40, 1 mM dithiothreitol, 1 mM phenylmethylsul-
fonyl fluoride) for 75 s. The nuclei were collected by centrifugation at
1000  g for 5 min and washed three times in cytoplasmic extraction
buffer without detergent. Nuclear proteins were extracted for immuno-
precipitation using nuclear extraction buffer (20 mM Tris, pH 8.0, 420
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl
fluoride) for 10 min. Total nuclear proteins were extracted by resus-
pending nuclei in RIPA buffer for 10 min. Then nuclear and cytoplasmic
fractions were diluted 1:5 in binding buffer, and 2 g of affinity-purified
YAP antisera was added to each fraction and tumbled 1 h at 4 °C. The
samples were collected on protein A beads, washed, and solubilized in
Laemmli sample buffer for SDS-PAGE and Western blot analysis.
Luciferase Assays—The cells were transfected with pGL3-Bax lucif-
erase and Lac-Z reporter plasmids either alone or with plasmids encod-
ing HA-YAP and/or HA-hnRNP U as noted in the figure legends. Empty
pCMV-HA vector was transfected to normalize the amount of DNA used
in each sample, and -galactosidase enzyme assays (Promega, Madison,
WI) were performed to normalize transfection efficiencies across sam-
ples. The cells were harvested in passive lysis buffer (Promega,
Madison, WI) for 18 h post-transfection, and the lysates were analyzed
using a Molecular Devices luminometer (Molecular Devices, Sunnyvale,
CA). Statistical significance was determined by Student’s t test.
RESULTS
YAP Associates with hnRNPU in Vitro—At the amino acid
level human YAP shares 45% sequence identity and 57% ho-
mology with its paralogue TAZ. One obvious difference at the
level of primary structure is a proline-rich amino terminus
found only in YAP (Fig. 1A). To identify proteins that associate
with YAP via this unique region, we immobilized 20 g of GST,
GST-YAP(1–57), or GST YAP(162–217) on glutathione-agarose
beads and incubated the fusion proteins with cell lysates pre-
pared from 16HBE14o cells labeled with [32P]orthophos-
phate. A unique 120-kDa phosphoprotein bound specifically to
GST-YAP(1–57) but not to GST alone or GST-YAP(162–217)
(Fig. 1B). We also analyzed proteins bound to GST or GST-
YAP(1–57) by silver staining (Fig. 1C). The 120-kDa protein
bound to GST-YAP(1–57) but not to GST alone, and the inter-
action was abolished when the affinity matrix was washed in
1 The abbreviations used are: hnRNP U, heterogeneous nuclear ribo-
nuclear protein U; Pol II, RNA polymerase II; CTD, carboxyl-terminal
domain; CTF, COOH-terminal fragment; GST, glutathione S-transfer-
ase; MALDI-TOF, matrix-assisted laser desorption ionization time-of-
flight; MS, mass spectrometry; HA, hemagglutinin; GFP, green fluores-
cent protein.
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buffers containing 500 mM NaCl to disrupt ionic interactions
(Fig. 1C, arrow). Using MALDI-TOF and electrospray tandem
MS/MS, we identified the interacting protein as hnRNP U (also
known as scaffold attachment factor A). To confirm the mass
spectrometry analysis, we performed identical pull-down as-
says using GST or GST-YAP(1–57) and analyzed the bound
fractions using a monoclonal antibody specific for hnRNP U
(33). As predicted by the mass spectrometry analysis, hnRNP U
specifically bound the affinity resin containing the GST-
YAP(1–57) fusion protein but did not associate with GST alone
(Fig. 1D). To determine whether an indirect association of YAP
and hnRNP U is mediated by nucleic acids, we repeated the
same experiments in the presence of RNase and DNase but
found that GST-YAP(1–57) still bound hnRNP U under these
conditions (not shown). Thus we conclude that nucleic acids do
not indirectly mediate the association of YAP and hnRNP U.
YAP and hnRNP U Co-localize in the Nucleus—For YAP and
hnRNP U to interact in vivo, they must co-localize, at least in
part, to the same subcellular compartment. Although YAP has
been described as a transcriptional co-activator based on its
ability to associate directly with multiple transcription factors
in vitro (11–14), the localization of endogenous YAP has not
been extensively studied. In polarized epithelial cells, YAP
localizes primarily to the apical membrane, and no protein was
detected in the nucleus (8). In fibroblasts, the localization of
YAP was studied by overexpression of the epitope-tagged pro-
tein with conflicting results (12, 14), and the localization of the
endogenous protein has never been studied. Therefore we
tested whether endogenous YAP localized to the nucleus,
where it could potentially interact with hnRNP U. HeLa cells
were stained with antibodies directed against YAP and hnRNP
U and the distribution of each protein studied by confocal
microscopy. A significant fraction of the endogenous YAP pro-
tein was found in the cytoplasm and on the plasma membrane;
however, we also detected endogenous YAP in the nucleus of
HeLa cells (Fig. 2A). As expected we also found significant
amounts of hnRNP U in the nucleus of HeLa cells; both YAP
and hnRNP U were distributed throughout the nucleoplasm, as
well as concentrated in speckled foci (Fig. 2A). Although far less
hnRNP U was detected in the cytoplasm of the cells, we con-
sistently observed a pool of the protein diffusely distributed
throughout the cytoplasm (Fig. 2A). We used subcellular frac-
tionation and Western blot analysis to confirm these results
and to determine the ratio of cytoplasmic and nuclear YAP.
Equal ratios of cytoplasmic and nuclear fractions were sepa-
rated by SDS-PAGE, and the purity of the fractions was as-
sessed by Western blot analysis of the cytoplasmic protein IB
(39, 40) or the nuclear histone deacetylase Sin3 (41) (Fig. 2B).
Consistent with our localization studies, YAP was found in
both nuclear and cytoplasmic fractions with 5- 20% of the
endogenous protein present in the nucleus based on densito-
metric analysis of multiple preparations. We were also able to
confirm our finding that some hnRNP U resides in the cyto-
plasm, although the majority of the protein clearly fractionated
with the nuclear compartment (Fig. 2C).
YAP Interacts with hnRNP U in Vivo—Because we detected
an interaction between YAP and hnRNP U in vitro and the two
proteins co-localize in cells, we next asked whether the two
proteins interacted in vivo. Furthermore, because both proteins
were found in nuclear and cytoplasmic compartments, we
asked whether the interaction of YAP and hnRNP U occurred
in the nucleus, in the cytoplasm, or in both subcellular com-
partments. Cells expressing HA-tagged full-length YAP were
separated into cytoplasmic and nuclear fractions, and the sol-
uble protein in each fraction was incubated with affinity-puri-
fied YAP antibodies or a nonimmune IgG control. After exten-
FIG. 1. hnRNP U binds the amino terminus of YAP. A, sequence analysis of the amino-terminal domains of human YAP and TAZ. Identical
amino acids are shaded black, whereas conservative substitutions are shaded gray. B, cells were labeled for 3 h with [32P]orthophosphate, lysed
in RIPA buffer, and then diluted 1:5 in binding buffer as described under “Materials and Methods.” The lysates were incubated with GST alone
(lane 1), GST-YAP(1–57) (lane 2), or GST-YAP(162–217) (lane 3) for 1 h and then washed in binding buffer. The samples were resolved on 9%
SDS-PAGE gels and applied to PhosphorImager screens. C, cell lysates were prepared as described in B and incubated with GST (lane 1),
GST-YAP(1–57) (lane 2), or GST-YAP(1–57) with 500 mM NaCl wash (lane 3). The bound proteins were analyzed on 9% SDS-PAGE gels and
visualized with silver staining. The arrow indicates proteins identified by mass spectrometry. D, cell lysates were prepared as described in B and
incubated with GST (lane 1) or GST-YAP(1–57) (lane 2). The bound proteins were fractionated on 9% SDS-PAGE gels, transferred to Immobilon-P,
and blotted with a monoclonal antibody against hnRNP U. A shorter exposure indicated that the monoclonal antibody recognized both bands of
the doublet visualized in B. In, input, representing 20% of the total cell lysate in each assay. All of the gels are representative of two to four
replicates with identical results.
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sive washing the bound fractions were separated by SDS-
PAGE and analyzed by Western blot analysis with HA
antibodies and with antibodies directed against hnRNP U.
Importantly, the distribution of HA-YAP was indistinguishable
from the distribution of endogenous YAP (not shown), and the
overexpressed protein was observed in both the nuclear and
cytoplasmic compartments. We found that YAP interacted with
hnRNP U selectively in the nuclear compartment (Fig. 3), even
though a pool of hnRNP U was available in the cytoplasmic
fraction for interaction (Fig. 3). Furthermore cytoplasmic YAP
was capable of protein-protein interaction because we reliably
detected the interaction of cytoplasmic HA-YAP and 14-3-3
(Fig. 3), a protein involved in sequestering YAP in the cyto-
plasm (10). Thus we conclude that YAP and hnRNP U interact
in vivo and that the interaction occurs selectively in the nuclei
of HeLa cells.
Interaction of YAP with hnRNP U Is Not Responsible for YAP
Translocation to the Nucleus—Multiple labs have proposed
that YAP cycles between the cytoplasm and nucleus to inte-
grate specific signal transduction events, but YAP contains no
classical nuclear localization sequence, and the mechanism by
which it enters the nucleus is unknown. Although hnRNP U
stably interacts with YAP only in the nuclear fraction, we
considered the possibility that one function of the hnRNP U-
YAP interaction was to shuttle YAP into the nucleus where the
two proteins remained stably associated. Therefore we asked
whether amino acids 1–57 of YAP, which mediate the interac-
tion with hnRNP U (Fig. 1), are necessary and sufficient for
targeting YAP to the nucleus in HeLa cells. Because the trun-
cated YAP protein was able to passively diffuse into the nu-
cleus, we fused full-length and truncated YAP proteins to a
triple-tandem green fluorescent protein tag (3XGFP) and com-
pared the distributions of 3XGFP and various 3XGFP-YAP
proteins, including YAP(1–57), which is capable of binding
hnRNP U, and YAP(58–474), which lacks the site of interac-
tion with hnRNP U.
HeLa cells were transiently transfected with 3XGFP alone,
3XGFP-YAP, 3XGFP-YAP(1–57), or 3XGFP-YAP(58–474).
The 3XGFP protein accumulated exclusively in the cytoplasm
(Fig. 4A). In contrast, 3XGFP-YAP localized to both the nucleus
and the cytoplasm in a distribution similar to the endogenous
YAP protein (Fig. 4B; see Fig. 2). The overexpressed 3XGFP-
YAP(1–57) protein localized predominantly to cytoplasm,
whereas 3XGFP-YAP(58–474) localized both to the nucleus
and the cytoplasm similar to full-length YAP (Fig. 4, C and D).
Because the majority of overexpressed 3XGFP-YAP(1–57) pro-
tein resides in the cytoplasm, whereas YAP(58–474) resides in
both the nucleus and the cytoplasm, the interaction of YAP
with hnRNP U mediated by this region is unlikely to play a role
in the translocation of YAP into the nucleus. Furthermore,
amino acids 1–57 of YAP are neither necessary nor sufficient to
target YAP to the nucleus.
hnRNP U Negatively Regulates YAP Co-activation of Bax
Transcription—Because YAP and hnRNP U interact in the
nucleus, we next asked whether hnRNP U had an effect on
known YAP functions in the nucleus. YAP was shown to ro-
bustly co-activate p73-mediated gene expression to regulate
the transcription of the pro-apoptotic gene Bax (10, 13). Be-
cause HeLa cells express significant amounts of p73 (42), we
tested whether co-expression of hnRNP U had an effect on the
ability of YAP to stimulate the expression of Bax. To do this we
used a reporter plasmid with a p73-responsive Bax promoter
upstream of the firefly luciferase gene. HeLa cells were tran-
FIG. 3. YAP and hnRNP U selectively interact in the nuclear
fraction. HeLa cells were transiently transfected with plasmid encoding
HA-YAP, harvested 18 h later, and separated into nuclear and cytoplas-
mic fractions as indicated. The cytoplasmic and nuclear fractions were
subjected to immunoprecipitation with preimmune IgG (lane 1) or anti-
YAP IgG (lane 2) for 1 h and collected on protein A beads for 45 min. The
samples were electrophoresed on 4- 20% gradient SDS-PAGE gels, trans-
ferred to Immobilon-P, and analyzed by Western blotting with HA,
hnRNP U, or pan-14-3-3 antibodies. The results are representative of
three experiments. IP, immunoprecipitation; IB, immunoblot.
FIG. 2. The localization of endoge-
nous YAP and hnRNP U in HeLa
cells. A, HeLa cells were fixed and
stained as described previously (36) using
a polyclonal antibody to YAP and a mono-
clonal antibody to hnRNP U followed by
the fluorescently labeled secondary anti-
bodies. The cells were visualized in xy
sections by confocal microscopy (scale bar,
20 m). Several different sections of the
cells were visualized, and the data pre-
sented are representative of two different
planes of focus to highlight nuclear and
cytoplasmic images. B, HeLa cells were
separated in cytoplasmic (cyt) and nuclear
(nuc) fractions as described under “Mate-
rials and Methods.” Equal ratios of each
fraction was resolved on 4–20% SDS-
PAGE gels and analyzed by Western blot-
ting as noted in the figure. Western blots
are representative of fractionation exper-
iments performed at least five times.
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siently transfected with the reporter construct plus empty vec-
tor, full-length YAP and/or hnRNP U. As reported previously
(10, 13), overexpression of YAP induced Bax-luciferase activity
8–12-fold above basal levels (Fig. 5). Overexpression of hnRNP
U alone had no effect on activation of the reporter gene, but
when co-expressed with full-length YAP, hnRNP U signifi-
cantly attenuated the ability of YAP to increase Bax-luciferase
activity (Fig. 5). Overexpressed YAP(58–474), lacking the ami-
no-terminal domain that mediates the interaction with hnRNP
U, robustly increased Bax-luciferase activity and did not differ
significantly from the effect observed when full-length YAP
was co-expressed (Fig. 5). However, in contrast to what we
observed with the full-length YAP protein, hnRNP U was un-
able to block the YAP(58–474)-mediated increase of Bax-lucif-
erase activity (Fig. 5). Therefore we conclude that the associa-
tion of hnRNP U and YAP is required for modulation of p73-
mediated Bax reporter gene activity in HeLa cells.
Furthermore we conclude that YAP and hnRNP U functionally
interact in the nucleus and that one outcome of the interaction
is to block the ability of YAP to function as a transcriptional
co-activator in some cellular contexts.
DISCUSSION
Here we show that YAP physically (Figs. 1 and 3) and func-
tionally (Fig. 5) interacts with hnRNP U, a multifunctional
nuclear protein and a constituent of the nuclear matrix and
scaffold (31, 32, 43–47). YAP associates with hnRNP U via a
proline-rich amino terminus lacking in the related protein TAZ
(Fig. 1). Thus the ability to associate with hnRNP U is another
distinguishing feature of these two related proteins and may
help explain differences in their cellular functions.
Our subcellular fractionation and localization studies clearly
show that YAP and hnRNP U are localized in both the cyto-
plasm and nucleus (Fig. 2); however, we were only able to
co-immunoprecipitate the two proteins from the nuclear frac-
tion (Fig. 3). Further biochemical studies will be required to
determine whether the association of YAP and hnRNP U oc-
curs in subcompartments of the nucleus including the matrix,
a site where hnRNP U is known to significantly accumulate
(32, 43). It is not clear why the YAP-hnRNP U association
occurs preferentially in the nucleus. One possibility is that YAP
and hnRNP U do indeed interact in the cytosol but with a lower
affinity than the interaction observed in the nucleus. It is also
possible that YAP and/or hnRNP U interact with other proteins
in the cytoplasm and that these protein interactions may pre-
vent the interaction between YAP and hnRNP U. Alterna-
tively, a nuclear-specific protein may mediate an indirect in-
teraction between YAP and hnRNP U. Because we identified
hnRNP U in pull-down assays from cell lysates, we cannot rule
out this possibility. However, sensitive silver staining ap-
proaches failed to visualize additional proteins eluting from the
GST-YAP(1–57) affinity matrix. Finally it is also possible that
the interaction of YAP and hnRNP U is regulated by compart-
ment-specific phosphorylation or dephosphorylation of one or
both proteins. Both YAP (6) and hnRNP U (Fig. 1B) are con-
stitutively phosphorylated, and Basu et al. (10) showed that
YAP is differentially phosphorylated in the cytoplasm and nu-
cleus. Furthermore, phosphorylation of YAP has already been
shown to promote specific protein-protein interactions in the
cytoplasm, where Akt-mediated phosphorylation at serine 127
leads to 14-3-3 binding (10). Regardless of the mechanism
involved in this compartment-specific interaction, it will be
important to compare the full complement of YAP-interacting
proteins in the nucleus and cytoplasm to gain a full apprecia-
tion of its cellular functions.
Epidermal growth factor receptor activation and subsequent
phosphorylation by Akt stimulates the nuclear exit of YAP (10),
but we know relatively little regarding how YAP enters the
nucleus where it functions to modulate transcription of a vari-
ety of genes (7, 10–14). Furthermore, it is unclear whether
there is a stable pool of nuclear YAP or whether specific extra-
cellular signals promote the nuclear accumulation of YAP. YAP
lacks any known nuclear localization signal; thus the associa-
tion with cytoplasmic proteins may play a key role in the
nuclear entry of YAP. For example, binding of heregulin to
ErbB-4 results in two proteolytic cleavages that release the
ErbB-4 intracellular COOH-terminal fragment (CTF) from the
membrane (48, 49). The CTF translocates from the cytoplasm
to the nucleus where it may affect the transcription of target
genes (7, 50). Because YAP associates with the plasma mem-
brane-associated ErbB-4 receptor and the CTF requires YAP
for stimulation of transcription via the Gal4 transactivation
system (7), YAP may translocate from the cytoplasm to the
nucleus in association with the ErbB-4 CTF. Because we found
hnRNP U in the cytoplasm (Fig. 2), and hnRNP U contains an
amino-terminal nuclear localization signal (30), we first con-
sidered the possibility that the association with hnRNP U
played a role in the translocation of YAP from the cytoplasm to
the nucleus. However, using triple GFP-tagged YAP fusion
proteins, we found YAP(1–57) excluded from the nucleus,
whereas full-length YAP and YAP(58–474) was found in both
the cytoplasm and in the nucleus (Fig. 4, B and D). Because
amino acids 1–57 of YAP mediate its interaction with hnRNP
U, we conclude that the YAP-hnRNP U interaction plays no
role in targeting YAP to the nucleus. Furthermore, the distri-
bution of GFP-YAP(58–474), which can not bind hnRNP U,
resembles that of full-length YAP (Fig. 4), implying that this
interaction does not play a major role in retaining YAP in the
nucleus.
Although the hnRNP U- YAP interaction does not play a role
in regulating the subcellular localization of YAP, our functional
studies show that co-expression of hnRNP U significantly at-
tenuates the ability of YAP to increase p73-driven Bax-lucifer-
ase activity in HeLa cells (Fig. 5). We do not yet understand
how hnRNP U modulates the ability of YAP to function as a
transcriptional co-activator. Interaction with hnRNP U may
directly block a binding site needed for YAP co-activation. This
is unlikely, because the proline-rich amino terminus that binds
hnRNP U is not the region of YAP implicated in transcriptional
co-activation. Alternatively, hnRNP U may shuttle YAP away
FIG. 4. hnRNP U is not responsible for translocating YAP to the
nucleus. HeLa cells were transiently transfected with cDNAs encoding
3XGFP (panel A), 3XGFP-YAP (panel B), 3XGFP-YAP(1-57) (panel C), or
3XGFP-YAP(58-474) (panel D). After 18 h the cells were fixed and ana-
lyzed by confocal microscopy (scale bar, 20 m). The figures are repre-
sentative of two separate transfection experiments and the visual exam-
ination of at least 100 GFP-positive cells.
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from sites of active gene transcription (Fig. 6). Evidence sup-
porting this model comes from studies demonstrating that
overexpression of hnRNP U represses glucocorticoid-mediated
transcription by recruiting the activated receptor to the nuclear
matrix (31, 51). The nuclear matrix may be involved in RNA
transcription and processing and is a repository for many tran-
scription factors, splicing factors (52), and proteins involved in
chromatin remodeling (53–55). Association of transcriptional
regulators with the nuclear matrix could serve multiple pur-
poses, including inhibition of transcription by sequestration
away from the sites of active transcription. Sequestration to
the nuclear matrix may also provide a local storage pool capa-
ble of rapid dynamic regulation without the need to recruit
proteins from the cytoplasm upon activation (56). Additionally,
because the sites of chromatin attachment to the nuclear matrix
serve as local gene expression loops, matrix-associated regions
could be specifically enriched for the factors needed to enhance
or repress the genes within these local active regions (57).
One intriguing possibility is that instead of directly acting on
YAP, hnRNP U may affect the function of YAP by acting on
RNA polymerase II (Pol II). Pol II contains a noncatalytic
COOH-terminal domain (CTD) that can be phosphorylated, a
prerequisite for transcript elongation (58, 59). Although
hnRNP U binds directly to the phosphorylated CTD of Pol II
(60), hnRNP U does not always localize to sites of active tran-
scription (61) and can be found in the nuclear matrix (62).
Therefore hnRNP U may sequester activated Pol II in the
nuclear matrix until it is needed. Alternatively, hnRNP U may
affect YAP co-activation by directly repressing transcriptional
elongation by activated Pol II. hnRNP U associates with tran-
scription factor IIH, a kinase complex known to phosphorylate
the Pol II CTD to enable transcript elongation (58, 63). Binding
of hnRNP U to transcription factor IIH inhibits the phospho-
rylation of the CTD (46). Thus transcriptional co-activation by
YAP may be inhibited indirectly if hnRNP U prevents the
phosphorylation (and activation) of Pol II. Although this model
is intriguing, hnRNP U fails to affect the function of YAP
proteins lacking the hnRNP U-binding site (Fig. 5). However, if
a ternary complex including YAP, Pol II, and hnRNP U was
formed because of other protein-protein interactions, this type
of indirect regulation could still occur. Further studies will be
needed to elucidate the mechanisms involved in YAP co-acti-
vation and to determine how hnRNPU U affects the nuclear
functions of YAP.
Another important question is whether hnRNP U affects other
nuclear functions of YAP. hnRNP U interacts with the amino
terminus of YAP and not with the YAP WW domains, the site of
binding for several transcription factors (13, 14). Thus hnRNP U
may modulate the ability of YAP to regulate the activity of
multiple transcription factors. Interestingly, the TEAD/TEF
transcription factors bind a region of YAP that overlaps with the
hnRNP U-binding site (12). Further studies will be needed to
determine whether hnRNP U and TEAD binding is competitive
or cooperative and whether the association of YAP and hnRNP U
attenuates TEAD transcriptional activity.
Together with work in a variety of laboratories, our data
FIG. 6. A model of compartment-specific interactions of YAP.
In the cytoplasm of epithelial cells YAP interacts with EBP50 at the
plasma membrane (8). Because EBP50 is known to interact with recep-
tors, ion channels, and signaling intermediates, this interaction may
recruit YAP (and it associated nonreceptor tyrosine kinase) into cell
surface-associated signaling complexes (64–66). In some cell types YAP
may associate with other PDZ proteins, including MUPP1 (12). In
addition YAP may interact with 14-3-3 proteins, and this interaction
may function to sequester YAP in the cytoplasm and away from its
nuclear targets. Currently, it is unknown whether 14-3-3 associates
with YAP in the plasma membrane pool or only in the cytoplasm, and
the relationship between these pools of YAP is poorly understood. In the
nucleus, YAP interacts with multiple transcription factors as well as
hnRNP U, a component of the nuclear matrix. Although the model
shows two separate pools of nuclear YAP, one at sites of active tran-
scription and one in the nuclear matrix in association with hnRNP U,
the existence of these pools and their relationship to each other has not
been explored. Tf, transcription factor.
FIG. 5. Functional analysis of the YAP-hnRNP U interaction. HeLa cells were transiently transfected 150 ng of the indicated plasmids
encoding HA-YAP or HA-YAP(58–474) with or without HA-hnRNP U, together with Bax-luciferase and Lac-Z reporter plasmids. The total amount
of transfected DNA was maintained constant by the addition of empty pCMV-HA plasmid when necessary. After 18 h the cell extracts were
prepared in passive lysis buffer, luciferase activity was measured, and the data were normalized to -galactosidase activity. The samples were
analyzed in triplicate, and the data are expressed as the fold change relative to the negative control and analyzed by Student’s t test. All of the
conditions were performed at least three times with similar results, and protein expression was verified by Western blot analysis with HA
antibodies in parallel dishes. *, p  0.001; †, p  0.001.
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suggest that YAP exists in the nucleus and in the cytoplasm in
multiple distinct pools (Fig. 6). For example, in the cytoplasm
YAP may target the plasma membrane by association with
PDZ proteins (8) or may exist in the cytoplasm in association
with 14-3-3 (10). Likewise, in the nucleus YAP may exist in
association with hnRNP U in the nuclear matrix or at sites of
active transcription in association with a variety of transcrip-
tion factors. Further work will be needed to clearly demon-
strate the existence of each of these protein complexes and to
clarify the relationship between the different pools of YAP
protein. Furthermore, it will be critical to define extracellular
signals that drive the accumulation of YAP preferentially in
one compartment or subcompartment of the cell. Given that
YAP has multiple protein interaction domains and is ubiqui-
tously expressed, tissue- and cell type-specific interactions are
also likely to help explain the functions of YAP as an adaptor
protein and as a regulator of gene transcription.
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